Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | USP2 | O75604 | 1/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.39 |
| ▸ | GPR119 | Q8TDV5 | 8/20 | 0.37 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 1/20 | 0.36 |
| ▸ | THRB | P10828 | 1/20 | 0.36 |
| ▸ | PTPN2 | P17706 | 1/20 | 0.36 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.36 |
| ▸ | PTPN6 | P29350 | 1/20 | 0.36 |
| ▸ | AVPR1A | P37288 | 1/20 | 0.36 |
| ▸ | SCD5 | Q86SK9 | 1/20 | 0.36 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | ATM | Q13315 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21710557 | 1.00 | USP2 (0.39) | USP2SMN1; SMN2GPR119RECQLKDM4E | |
| SCHEMBL21681621 | 0.84 | HHAT (0.36) | — | |
| SCHEMBL21681614 | 0.84 | HHAT (0.36) | — | |
| SCHEMBL28602735 | 0.82 | KDM4E (0.38) | USP2SMN1; SMN2GPR119KDM4EMAPT | |
| SCHEMBL20487416 | 0.82 | KDM4E (0.38) | USP2SMN1; SMN2GPR119KDM4EMAPT | |
| SCHEMBL1807425 | 0.79 | OPRL1 (0.47) | USP2SMN1; SMN2GPR119AVPR1A | |
| SCHEMBL23002541 | 0.78 | USP2 (0.44) | USP2SMN1; SMN2GPR119RECQLKDM4E | |
| SCHEMBL26066300 | 0.77 | GPR119 (0.36) | USP2SMN1; SMN2GPR119RECQLPTPN2 | |
| SCHEMBL21710554 | 0.77 | USP2 (0.40) | USP2SMN1; SMN2GPR119RECQLPTPN2 | |
| SCHEMBL18579748 | 0.77 | USP2 (0.40) | USP2SMN1; SMN2GPR119RECQLPTPN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11008336-B2 | Compounds useful for inhibiting RORγt | ELI LILLY AND COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| US-11008336-B2 | Compounds useful for inhibiting RORγt | ELI LILLY AND COMPANY (US) | 2021-05-18 | — | — | US | disclosed |
| EP-3589638-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2021-04-07 | — | — | EP | disclosed |
| EP-3589638-B1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | LILLY CO ELI (US) | 2021-04-07 | — | — | EP | disclosed |
| US-20200048279-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY | 2020-02-13 | — | — | US | disclosed |
| US-20200048279-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY | 2020-02-13 | — | — | US | disclosed |
| WO-2018160550-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | ELI LILLY AND COMPANY (US) | 2018-09-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11008336-B2 | Compounds useful for inhibiting RORγt | RORB, RORC, RORA | USP2 3449/4885SMN1; SMN2 4789/4885GPR119 139/4885 |
| US-20200048279-A1 | COMPOUNDS USEFUL FOR INHIBITING ROR-GAMMA-T | RORC, RORB, RORA | USP2 3407/4885SMN1; SMN2 4622/4885GPR119 473/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.